Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$23.3M Buy
108,052
+11,188
+12% +$2.14M 0.03% 389
2026
Q1
$17.8M Sell
96,864
-28,034
-22% -$5.17M 0.03% 418
2025
Q4
$22M Buy
124,898
+9,192
+8% +$1.5M 0.04% 367
2025
Q3
$16.2M Buy
115,706
+7,032
+6% +$951K 0.03% 433
2025
Q2
$13.6M Buy
108,674
+6,945
+7% +$865K 0.03% 456
2025
Q1
$13.9M Buy
101,729
+13,998
+16% +$2M 0.03% 399
2024
Q4
$13.4M Buy
87,731
+69,199
+373% +$11.7M 0.03% 387
2024
Q3
$3.59M Buy
18,532
+258
+1% +$54K 0.01% 506
2024
Q2
$4.24M Sell
18,274
-13,849
-43% -$3.01M 0.01% 519
2024
Q1
$6.93M Sell
32,123
-34,836
-52% -$8.16M 0.02% 484
2023
Q4
$17.3M Buy
66,959
+17,770
+36% +$4.36M 0.06% 353
2023
Q3
$12.6M Sell
49,189
-8,072
-14% -$2.16M 0.05% 391
2023
Q2
$16.3M Buy
57,261
+24,493
+75% +$7.29M 0.07% 352
2023
Q1
$9.11M Sell
32,768
-13,292
-29% -$3.68M 0.04% 474
2022
Q4
$12.8M Buy
46,060
+24,112
+110% +$6.81M 0.06% 405
2022
Q3
$5.86M Sell
21,948
-3,138
-13% -$666K 0.03% 543
2022
Q2
$5.12M Sell
25,086
-12,283
-33% -$2.51M 0.03% 582
2022
Q1
$7.87M Sell
37,369
-8,733
-19% -$1.9M 0.04% 488
2021
Q4
$11.1M Sell
46,102
-3,527
-7% -$907K 0.05% 375
2021
Q3
$14M Buy
49,629
+1,069
+2% +$350K 0.06% 306
2021
Q2
$16.8M Sell
48,560
-2,023
-4% -$613K 0.07% 264
2021
Q1
$14.2M Sell
50,583
-1,610
-3% -$434K 0.07% 258
2020
Q4
$12.8M Buy
52,193
+1,188
+2% +$306K 0.07% 273
2020
Q3
$14.5M Sell
51,005
-3,203
-6% -$893K 0.09% 208
2020
Q2
$14.5M Sell
54,208
-6,890
-11% -$2.07M 0.09% 196
2020
Q1
$19.3M Sell
61,098
-2,738
-4% -$831K 0.14% 135
2019
Q4
$18.9M Sell
63,836
-1,153
-2% -$320K 0.11% 160
2019
Q3
$15.1M Sell
64,989
-7,132
-10% -$1.66M 0.1% 182
2019
Q2
$16.9M Sell
72,121
-2,337
-3% -$540K 0.12% 172
2019
Q1
$17.6M Sell
74,458
-1,567
-2% -$493K 0.12% 174
2018
Q4
$22.9M Sell
76,025
-21,516
-22% -$6.87M 0.17% 132
2018
Q3
$34.5M Sell
97,541
-8,962
-8% -$3.09M 0.19% 120
2018
Q2
$30.9M Sell
106,503
-1,389
-1% -$391K 0.18% 123
2018
Q1
$29.5M Sell
107,892
-10,095
-9% -$3.13M 0.18% 126
2017
Q4
$37.6M Sell
117,987
-17,373
-13% -$5.57M 0.21% 115
2017
Q3
$42.4M Buy
135,360
+660
+0.5% +$195K 0.23% 109
2017
Q2
$36.5M Buy
134,700
+260
+0.2% +$68.8K 0.2% 120
2017
Q1
$36.8M Sell
134,440
-8,967
-6% -$2.54M 0.21% 111
2016
Q4
$40.7M Buy
143,407
+218
+0.2% +$64.6K 0.24% 95
2016
Q3
$44.8M Sell
143,189
-1,800
-1% -$533K 0.28% 82
2016
Q2
$35.1M Buy
144,989
+20,568
+17% +$5.42M 0.24% 95
2016
Q1
$32.4M Sell
124,421
-3,177
-2% -$839K 0.24% 90
2015
Q4
$39.1M Sell
127,598
-2,967
-2% -$853K 0.3% 75
2015
Q3
$38.1M Sell
130,565
-13,193
-9% -$4.36M 0.32% 77
2015
Q2
$58.1M Buy
143,758
+6,878
+5% +$2.76M 0.41% 60
2015
Q1
$57.8M Buy
136,880
+1,934
+1% +$762K 0.4% 59
2014
Q4
$45.8M Buy
134,946
+19,966
+17% +$6.46M 0.36% 67
2014
Q3
$38M Sell
114,980
-638
-0.6% -$210K 0.3% 76
2014
Q2
$36.5M Buy
115,618
+53
+0% +$16K 0.28% 83
2014
Q1
$35.3M Sell
115,565
-917
-0.8% -$291K 0.29% 83
2013
Q4
$32.6M Buy
116,482
+36
+0% +$9.31K 0.27% 88
2013
Q3
$28M Buy
116,446
+13,600
+13% +$3.04M 0.25% 100
2013
Q2
$22.1M Buy
+102,846
New +$22M 0.22% 118

Other funds holding BIIB

Aviva's BIIB Position: Q2 2026 in Review

Aviva increased its Biogen (BIIB) stake by 12% in Q2 2026, buying an estimated $2.14M and bringing the position to 108,052 shares worth $23.3M. The position accounts for 0.03% of the portfolio, ranked #389.

Aviva first reported a position in BIIB in Q2 2013 and has held it in 53 quarters since. The position peaked at $58.1M in Q2 2015. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Aviva held 108,052 shares of Biogen worth $23.3M as of Q2 2026.
  • Aviva bought 11,188 Biogen shares in Q2 2026, an estimated $2.14M.
  • Biogen made up 0.03% of Aviva's portfolio in Q2 2026, its #389 holding.
  • Aviva first reported a position in Biogen in Q2 2013 and has held it in 53 quarters since.
  • Aviva's Biogen position peaked at $58.1M in Q2 2015.
  • 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.